Cytokinetics (STU:KK3A) Cyclically Adjusted PB Ratio: (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:KK3A Cytokinetics Inc STU:KK3A
57 GF Score
Price €60.04
GF Value €193.07
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cytokinetics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cytokinetics  (STU:KK3A) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cytokinetics Cyclically Adjusted PB Ratio Related Terms


Cytokinetics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Cytokinetics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytokinetics Cyclically Adjusted PB Ratio Chart

Cytokinetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.69 29.53 77.88 72.73 0.00

Cytokinetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.71 163.44 477.06 0.00 0.00

STU:KK3A vs IONS, APGE, KYMR: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Cytokinetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Cyclically Adjusted PB Ratio falls into.


STU:KK3A
57GF Score
Cytokinetics Inc STU:KK3A
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytokinetics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cytokinetics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Cytokinetics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.094/333.9520*333.9520
=-1.094

Current CPI (Jun. 2026) = 333.9520.

Cytokinetics Quarterly Data

Book Value per Share CPI Adj_Book
201609 1.861 241.428 2.574
201612 2.201 241.432 3.044
201703 2.054 243.801 2.814
201706 2.870 244.955 3.913
201709 2.309 246.819 3.124
201712 1.695 246.524 2.296
201803 1.494 249.554 1.999
201806 1.179 251.989 1.562
201809 0.819 252.439 1.083
201812 0.415 251.233 0.552
201903 0.052 254.202 0.068
201906 -0.074 256.143 -0.096
201909 -0.308 256.759 -0.401
201912 -0.165 256.974 -0.214
202003 -0.701 258.115 -0.907
202006 -0.986 257.797 -1.277
202009 1.807 260.280 2.318
202012 1.305 260.474 1.673
202103 0.807 264.877 1.017
202106 0.193 271.696 0.237
202109 2.563 274.310 3.120
202112 2.529 278.802 3.029
202203 1.221 287.504 1.418
202206 1.240 296.311 1.398
202209 -0.172 296.808 -0.194
202212 -1.066 296.797 -1.199
202303 -2.205 301.836 -2.440
202306 -3.183 305.109 -3.484
202309 -4.306 307.789 -4.672
202312 -3.441 306.746 -3.746
202403 -3.501 312.332 -3.743
202406 0.862 314.175 0.916
202409 -0.106 315.301 -0.112
202412 -1.106 315.605 -1.170
202503 -2.069 319.799 -2.161
202506 -2.626 322.561 -2.719
202509 -3.632 324.800 -3.734
202512 -4.568 324.054 -4.708
202603 -5.774 330.213 -5.839
202606 -1.094 333.952 -1.094

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Cytokinetics (STU:KK3A) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of €60.04 is trading 68.9% below its estimated GF Value™ of €193.07. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for STU:KK3A:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €193.07 vs. price of €60.04 (68.9% below fair value)
  • GF Score™: 57/100 with 7 warning signs

No single metric tells the full story. See the STU:KK3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cytokinetics Business Description

Other Exchanges CYTK:USA1CYTK:Italy
Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
57GF Score

Get the complete analysis for STU:KK3A

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€60.04
Price
€193.07
GF Value